Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: New Appointments at Biocept, Novacyt, Centogene, Illumina, More

Biocept: Linda Rubinstein, Antonino Morales, Samuel Riccitelli

Biocept has appointed Linda Rubinstein and Antonino Morales to its board of directors, effective immediately. The company also named Samuel Riccitelli as chairman of the board, succeeding longtime chair David Hale and interim chair Faye Wilson, both of whom remain directors.

Rubinstein has been a partner at FLG Partners, providing consulting services to life science and other companies such as Apexigen, ArmaGen, Five Prime, Kezar Life Sciences, Ingenuity Systems, iPierian, and True North. Previously, she was a principal at RDJ Advisors, and served as vice president and CFO at Solexa. Morales is a CPA who has worked with leading organizations such as Citibank, Bank of America, Arthur Anderson, and Mazda North America. Morales was president and CEO of Apoyo Financiero, a California-based community development financial institution.

Riccitelli was appointed to Biocept's board in October 2020 and currently serves as an independent consultant to healthcare companies and as a director of OrthoPediatrics.


Novacyt: David Allmond, Graham Mullis

Clinical diagnostics company Novacyt announced the appointment of David Allmond as CEO and a member of its board of directors, effective Oct. 18.

Allmond is chief business officer at Amryt Pharma, a rare and orphan disease drug company. He previously held sales and marketing roles at Amgen, Celgene, and Aegerion Pharmaceuticals.

Graham Mullis is retiring and will stand down as the company's CEO and board member.


Centogene: Patrice Denèfle

Centogene has appointed Patrice Denèfle as CSO, effective Aug. 16. He will succeed Phil Lambert, who decided to leave the company, which he joined in late 2019. Denèfle comes to Centogene from 4P-Pharma, where he was CSO. Prior to that, he was general manager of the Roche Institute for Research and Translational Medicine, and he held senior roles at Sanofi Aventis and Ipsen. He also served as CSO at rare disease biotech firm Genethon. Denèfle holds a Ph.D. in molecular biology and biotechnology from the Pasteur Institute.


Illumina: Luke Hickey

Illumina has hired Luke Hickey as VP of regional marketing. Hickey comes to Illumina from Pacific Biosciences, where he led strategic marketing, including the launch of the Sequel IIe system. He has more than 20 years of experience in the life sciences industry, previously having worked at Affymetrix, Qiagen, Incyte Genomics, and the University of California, San Diego School of Medicine. Hickey has an MBA from the University of California, Berkeley Haas School of Business.


For additional recent items on executive appointments and promotions in omics and molecular diagnostics, please see the People in the News page on our website.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.